194 related articles for article (PubMed ID: 34527166)
1. Blastoid mantle cell lymphoma presenting as acute leukemia: a case report.
Dongre A; Kanchankar N; Deshmukh M; Wasnik D; Dongre T
Pan Afr Med J; 2021; 39():150. PubMed ID: 34527166
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
3. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
Damon LE; Johnson JL; Niedzwiecki D; Cheson BD; Hurd DD; Bartlett NL; Lacasce AS; Blum KA; Byrd JC; Kelly M; Stock W; Linker CA; Canellos GP
J Clin Oncol; 2009 Dec; 27(36):6101-8. PubMed ID: 19917845
[TBL] [Abstract][Full Text] [Related]
4. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
5. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation in patients with mantle cell lymphoma.
Oinonen R; Jantunen E; Itälä M; Lehtinen T; Kuittinen O; Franssila K; Wiklund T; Elonen E
Leuk Lymphoma; 2002 Jun; 43(6):1229-37. PubMed ID: 12152990
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Doorduijn JK; Zijlstra JM; Lugtenburg PJ; Kersten MJ; Böhmer LH; Minnema MC; MacKenzie MA; van Marwijk Kooij R; de Jongh E; Snijders TJF; de Weerdt O; van Gelder M; Hoogendoorn M; Leys RBL; Kibbelaar RE; de Jong D; Chitu DA; Van't Veer MB; Kluin-Nelemans HC
Br J Haematol; 2020 Aug; 190(3):385-393. PubMed ID: 32150297
[TBL] [Abstract][Full Text] [Related]
8. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.
Jacobsen E; Freedman A
Curr Opin Oncol; 2004 Mar; 16(2):106-13. PubMed ID: 15075900
[TBL] [Abstract][Full Text] [Related]
9. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
Dreyling M; Lenz G; Hoster E; Van Hoof A; Gisselbrecht C; Schmits R; Metzner B; Truemper L; Reiser M; Steinhauer H; Boiron JM; Boogaerts MA; Aldaoud A; Silingardi V; Kluin-Nelemans HC; Hasford J; Parwaresch R; Unterhalt M; Hiddemann W
Blood; 2005 Apr; 105(7):2677-84. PubMed ID: 15591112
[TBL] [Abstract][Full Text] [Related]
10. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
11. Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation.
Aurer I
Curr Opin Oncol; 2019 Sep; 31(5):374-379. PubMed ID: 31233483
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
[TBL] [Abstract][Full Text] [Related]
13. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
Martin P; Chadburn A; Christos P; Furman R; Ruan J; Joyce MA; Fusco E; Glynn P; Elstrom R; Niesvizky R; Feldman EJ; Shore TB; Schuster MW; Ely S; Knowles DM; Chen-Kiang S; Coleman M; Leonard JP
Ann Oncol; 2008 Jul; 19(7):1327-1330. PubMed ID: 18349031
[TBL] [Abstract][Full Text] [Related]
14. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
15. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.
Tam CS; Khouri IF
Leuk Lymphoma; 2009 Aug; 50(8):1239-48. PubMed ID: 19562639
[TBL] [Abstract][Full Text] [Related]
16. Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a multi-institutional cohort in Taiwan.
Wang YH; Yu SC; Ko BS; Yang YT; Yao M; Tang JL; Huang TC
Int J Hematol; 2020 Sep; 112(3):385-394. PubMed ID: 32519171
[TBL] [Abstract][Full Text] [Related]
17. Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue.
Salhotra A; Shan Y; Tsai NC; Sanchez JF; Aldoss I; Ali H; Paris T; Spielberger R; Cao TM; Nademanee A; Forman SJ; Chen R
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1264-1268. PubMed ID: 28434928
[TBL] [Abstract][Full Text] [Related]
18. Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma.
Nastoupil LJ; Shenoy PJ; Ambinder A; Koff JL; Nooka AK; Waller EK; Langston A; Seward M; Kaufman JL; Bernal-Mizrachi L; King N; Lechowicz MJ; Lonial S; Sinha R; Flowers CR
Leuk Lymphoma; 2015 Feb; 56(2):383-9. PubMed ID: 24828864
[TBL] [Abstract][Full Text] [Related]
19. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
Kanaji N; Ishibashi K; Uno H; Hino N
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
[TBL] [Abstract][Full Text] [Related]
20. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
Ogura M; Yamamoto K; Morishima Y; Wakabayashi M; Tobinai K; Ando K; Uike N; Kurosawa M; Gomyo H; Taniwaki M; Nosaka K; Tsukamoto N; Shimoyama T; Fukuhara N; Yakushijin Y; Ohnishi K; Miyazaki K; Sawada K; Takayama N; Hanamura I; Nagai H; Kobayashi H; Usuki K; Kobayashi N; Ohyashiki K; Utsumi T; Kumagai K; Maruyama D; Ohmachi K; Matsuno Y; Nakamura S; Hotta T; Tsukasaki K;
Cancer Sci; 2018 Sep; 109(9):2830-2840. PubMed ID: 29957865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]